About Us
ABOUT GENPRO
While Genpro’s products and services can improve drug development’s evidence creation, medical writing, and statistics, our advanced solutions using AI and Machine Learning for RWE and Epidemiology help speed up the research process. We are a group of medics, statisticians, technologists, and medical writers that are committed to providing the highest quality healthcare services possible.
OUR MISSION
We aim to simplify & accelerate our client’s research, achieving their goals by providing knowledge-driven innovative solutions with the highest quality products and services. We do this with the understanding that this could lead to the improvement of health and betterment of many around the world.
WHO WE ARE
Genpro Research started by technologists, biostatisticians, and clinicians to make an impact on the way we use data from all sources, to make development decisions in clinical trials. We work with you to provide a dedicated, communicative team in Biostatistics & DM/Programming, and Medical Writing. And for our larger clients that require a technology partner, we come from a clinical background and understand drug development and scientific challenges. We have engineered a platform, called MaiA, that uses Machine Learning and Natural Language Processing algorithms to enable automation of several processes related to competitive intelligence and depth in understanding all literature sources related to the diverse needs of patients, safety issues, economic evaluations of treatments amongst many other areas related to drug development. Our team is based in US, EU, New Zealand, and India.
Next-generation Services & Technology Partner For The Pharmaceutical, Biotechnology, & Medical Devices Industry.
Genpro Research is a next-generation services and technology partner for the pharmaceutical, biotechnology, and medical devices industry. Our tools use Artificial Intelligence, Machine Learning, and Natural Language Processing algorithms to enable automation of several processes throughout drug development and post-launch activities. We provide advanced solutions in Biostatistics & Programming, Medical Writing, and Regulatory Submissions. Genpro has a diverse talent pool of professionals with several years of industry experience along with a young and energetic set of professionals from some of the leading institutions.
Genpro has launched MaiA, an advanced end-to-end framework that increases efficiency and mitigates the pain points of literature reviews. This platform quickly produces quality literature review summaries/ disease context summaries/ TA landscaping and Systematic Literature Reviews (SLRs) for Epidemiology, medical affairs, and medical information teams. It can reduce the cognitive workload of the writers and analysis by 50-70%. MaiA was co-developed and tested with one of the world’s top five pharma companies. Genpro provides an excellent work-life balance by adopting global Flexi work practices. Genpro team has been working for more than 15 years in NDA/ BLA/PMA submissions, interacting with FDA/ EMEA & PMDA, and actively collaborating with academic, industry, and FDA working groups.
EXECUTIVE LEADERSHIP
Dr. Sachin Marulkar
President & Chief Executive Officer
Anoop P Ambika
Chief Technology Officer
Kapil Khambholja Ph.D
Chief Scientific Officer
Limna Salim
Director, Biometrics
Shariq Alavi
Vice President of Business Development
Natasa Rajicic
Consulting Biostatistician
Vikash Jain
Head of Statistical Programming
Ramadevi Ramanathan
Manager-Compliance & Quality Assurance
Salih Siam
Senior Director,Sales & Business Development
Sindhu Pillai
Director - India Operations
Gheorghe Doros Ph.D
Director, Statistical Consulting
BIOMETRICS & STRATEGIC CONSULTING
Akhil Vijayan
Manager- Statistical Programming
Ajith Nair
Senior Manager- Clinical Data Standards
Roshan Stanley
Manager- Clinical Data Analytics
PRODUCT DEVELOPMENT
Vishnu Kurup M K
Product Manager
Syed Junaid Ahmed
Project Manager
Sruthi Pradeep
Product Manager
Praveen S
Project Lead UI
SCIENTIFIC ADVISORY BOARD
Dr. Philip T. Lavin
PhD, FASA, FRAPS
Dr. Lavin is an internationally well-known drug developer and Biostatistician with a long history of supporting clinical trials. He was a member of the Biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affliated for over 25 years. He co-founded Boston Biostatistics which became Aptiv Solutions before being acquired by ICON plc. Dr. Lavin has authored or co-authored 160 peer-reviewed publications in the medical and statistical literature. Dr. Lavin has been the Lead Biostatistician for 64 FDA approvals to date including 39 PMAs (16 orthopaedic, 7 cardiovascular). Dr. Lavin has continuously worked on various device projects in cardiovascular, orthopaedics, periodontal indications plus In-vitro diagnostics, and imaging. Dr. Lavin received his Ph.D. in Applied Mathematics from Brown University in 1972. He is the only person to be elected a Fellow of the American Statistical Association and the Regulatory Affairs Professional Society reflecting his many pioneering contributions to statistics, regulatory approvals, and medicine. He has been associated and working with the Genpro International team for over 10 years.
Dr. Paul Azunre
PhD
Paul Azunre holds a PhD in Computer Science from MIT and has served as a Principal Investigator on several DARPA research programs. He founded Algorine Inc., a Research Lab dedicated to advancing AI/ML and identifying scenarios where they can have a significant social impact. Paul also co-founded Ghana NLP, an open source initiative focused on using NLP and Transfer Learning with Ghanaian and other low-resource languages. He also serves as Director of Research at Dun & Bradstreet, a company helping businesses manage supply chain risk and other business analytics challenges. He is the author of the recently published book “Transfer Learning for NLP“ by Manning Publications.
Dr. Mark Chang
PhD
Dr. Mark Chang has over 20 years of experience as a statistician and, he is the founder of AG Inception for Artificial General Intelligence Research. Previously, He served as Sr. Vice President, Strategic Statistical Consulting at Veristat, Vice President of Biometrics at AMAG Pharmaceuticals and, director and scientific fellow at Millennium/Takeda Pharmaceuticals. Dr. Chang is a fellow of the American Statistical Association and an adjunct professor of Biostatistics at Boston University. He is a co-founder of the International Society for Biopharmaceutical Statistics, co-chair of the Biotechnology Industry Organization (BIO) Adaptive Design Working Group, and a member of the Multiregional Clinical Trial (MRCT) Expert Group. He has published 11 books, including Artificial Intelligence for Drug Development, Precision Medicine and Healthcare, Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials, and many more.
Babu Sivadasan
B.S.
Babu Sivadasan is a serial entrepreneur and executive with more than 25 years of experience in product engineering, operations, mergers and acquisitions, and corporate leadership. Mr. Sivadasan has co-founded two public companies that are Envestnet and Stamps.com and, he was also instrumental in building early-stage start-ups and large enterprise software companies. Mr. Sivadasan is an alumnus of Stanford University SEP and has a B.S in Computer Science and Engineering from the University of Kerala.
